Association between time to disease progression end points and overall survival in patients with neuroendocrine tumors

References

• Shi Q, Sargent DJ. Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials. Int J Clin Oncol. 2009;14(2):102–111.
   PubMed Web of Science ®Google Scholar
• Sargent DJ, Hayes DF. Assessing the measure of a new drug: is survival the only thing that matters? J Clin Oncol. 2008;26(12):1922–1923.
   PubMed Web of Science ®Google Scholar
• Lebwohl D, Kay A, Berg W, Baladi JF, Zheng J. Progression-free survival: gaining on overall survival as a gold standard and accelerating drug development. Cancer J. 2009;15(5):386–394.
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biological Evaluation and Research. Guidance for Industry: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. 2007. Available from: http://www.fda.gov/downloads/drugsGuidanceComplianceRegulatoyInformation/Guidance/UCM071590.pdf. Accessed May 27, 2014.
   Google Scholar
• Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst. 2009; 101(23):1642–1649.
   PubMed Web of Science ®Google Scholar
• Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–3072.
   PubMed Web of Science ®Google Scholar
• Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol. 2008;19(10):1727–1733.
   PubMed Web of Science ®Google Scholar
• Arnold R, Rinke A, Klose KJ, et al. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol. 2005;3(8):761–771.
   PubMed Web of Science ®Google Scholar
• Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol. 2008;26(20):3403–3410.
   PubMed Web of Science ®Google Scholar
• Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol. 2008;26(26):4311–4318.
   PubMed Web of Science ®Google Scholar
• Rinke A, Muller HH, Schade-Brittinger C, et al; PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656–4663.
   PubMed Web of Science ®Google Scholar
• Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501–513.
   PubMed Web of Science ®Google Scholar
• Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol. 2010;28(1):69–76.
   PubMed Web of Science ®Google Scholar
• Yao JC, Shah MH, Ito T, et al; RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364(6):514–523.
   PubMed Web of Science ®Google Scholar
• Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25(13):1753–1759.
   PubMed Web of Science ®Google Scholar
• Burzykowski T, Buyse M, Piccart-Gebhart MJ, et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol. 2008;26(12):1987–1992.
   PubMed Web of Science ®Google Scholar
• Kulke MH, Siu LL, Tepper JE, et al. Future directions in the treatment of neuroendocrine tumors: Consensus report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting. J Clin Oncol. 2011;29(7):934–943.
   PubMed Web of Science ®Google Scholar
• Singh S, Law C. Utility of progression-free survival as a primary endpoint in clinical studies of advanced neuroendocrine tumors. Ann Oncol. 2010;21:viii 265 (Abstr 851P).
   Google Scholar
• Murphy G, Perras C, Desjardin B, et al. Technology report number 111. Ottawa, Canada: Canadian Agency for Drugs and Technologies in Health; 2008. Available from: http://www.cadth.ca/media/pdf/H0348_Octreotide_tr_e.pdf. Accessed May 27, 2014.
   Google Scholar
• Buyse M, Burzykowski T, Carroll K, et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol. 2007;25(33):5218–5224.
   PubMed Web of Science ®Google Scholar
• Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Pitot HC, Burch PA, Kvols LK, Mahoney MR, Rubin J. A phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors. Cancer. 2001;91(8):1543–1548.
   PubMed Web of Science ®Google Scholar
• Bajetta E, Ferrari L, Procopio G, et al. Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours. Ann Oncol. 2002;13(4):614–621.
   PubMed Web of Science ®Google Scholar
• Kulke MH, Kim H, Clark JW, et al. A Phase II trial of gemcitabine for metastatic neuroendocrine tumors. Cancer. 2004;101(5):934–939.
   PubMed Web of Science ®Google Scholar
• Stuart K, Levy DE, Anderson T, et al. Phase II study of interferon gamma in malignant carcinoid tumors (E9292): a trial of the Eastern Cooperative Oncology Group. Invest New Drugs. 2004;22(1):75–81.
   Web of Science ®Google Scholar
• Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG; Eastern Cooperative Oncology Group. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol. 2005;23(22):4897–4904.
   PubMed Web of Science ®Google Scholar
• Ducreux MP, Boige V, Leboulleux S, et al. A Phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with pretreated gastroenteropancreatic well-differentiated endocrine carcinomas. Oncology. 2006;70(2):134–140.
   Web of Science ®Google Scholar
• Hainsworth JD, Spigel DR, Litchy S, Greco FA. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study. J Clin Oncol. 2006;24(22):3548–3554.
   PubMed Web of Science ®Google Scholar
• Kulke MH, Wu B, Ryan DP, et al. A Phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors. Dig Dis Sci. 2006;51(6):1033–1038.
   PubMed Web of Science ®Google Scholar
• Valkema R, Pauwels S, Kvols LK, et al. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med. 2006;36(2):147–156.
   PubMed Web of Science ®Google Scholar
• Correale P, Sciandivasci A, Intrivici C, et al. Chemo-hormone therapy of non-well-differentiated endocrine tumours from different anatomic sites with cisplatinum, etoposide and slow release lanreotide formulation. Br J Cancer. 2007;96(9):1343–1347.
   Web of Science ®Google Scholar
• Yao JC, Zhang JX, Rashid A, et al. Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res. 2007;13(1):234–240.
   PubMed Web of Science ®Google Scholar
• Kwekkeboom DJ, De Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26(13):2124–2130.
   PubMed Web of Science ®Google Scholar
• Dahan L, Bonnetain F, Rougier P, et al. Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710. Endocr Relat Cancer. 2009;16(4):1351–1361.
   PubMed Web of Science ®Google Scholar
• Bushnell DL Jr, O’Dorisio TM, O’Dorisio MS, et al. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol. 2010; 28(10):1652–1659.
   PubMed Web of Science ®Google Scholar
• Turner NC, Strauss SJ, Sarker D, et al. Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br J Cancer. 2010;102(7):1106–1112.
   PubMed Web of Science ®Google Scholar
• Pavel ME, Hainsworth JD, Baudin E, et al; RADIANT-2 Study Group. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011;378(3808):2005–2012.
   Google Scholar
• Delea TE, Khuu A, Kay A, Zheng J, Baladi JF. Association between treatment effects on disease progression (DP) endpoints and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2009;27:S105.
   Google Scholar
• Louvet C, de Gramont A, Tournigand C, Artru P, Maindrault-Goebel F, Krulik M. Correlation between progression free survival and response rate in patients with metastatic colorectal carcinoma. Cancer. 2001;91(11):2033–2038.
   Web of Science ®Google Scholar
• Sargent DJ, Wieand HS, Haller DG, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2005;23(34):8664–8670.
   PubMed Web of Science ®Google Scholar
• Buyse M. Is PFS a “valid” surrogate for OS in advanced ovarian cancer? A meta-analysis. North Bethesda, MD, USA: Public Workshop on Endpoints for Ovarian Cancer; 2006. Available from: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/Development Resources/CancerDrugs/ucm094610.pdf. Accessed May 27, 2014.
   Google Scholar
• Johnson KR, Ringland C, Stokes BJ, et al. Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. Lancet Oncol. 2006;7(9):741–746.
   PubMed Web of Science ®Google Scholar
• Knox JJ. Progression-free survival as endpoint in metastatic RCC? Lancet. 2008;372(9637):427–429.
   Web of Science ®Google Scholar
• Sherrill B, Amonkar M, Wu Y, et al. Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer. Br J Cancer. 2008;99(10):1572–1578.
   PubMed Web of Science ®Google Scholar
• Verweij J, Therasse P, Eisenhauer E. Cancer clinical trial outcomes: any progress in tumour-size assessment? Eur J Cancer. 2009;45(2):225–227.
   Web of Science ®Google Scholar
• Jaffe CC. Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol. 2006;24(20):3245–3251.
   PubMed Web of Science ®Google Scholar
• Sargent DJ, Rubinstein L, Schwartz L, et al. Validation of novel imaging methodologies for use as cancer clinical trial end-points. Eur J Cancer. 2009;45(2):290–299.
   PubMed Web of Science ®Google Scholar
• Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364(9440):1127–1134.
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247.
   PubMed Web of Science ®Google Scholar
• Massironi S, Sciola V, Peracchi M, Ciafardini C, Spampatti MP, Conte D. Neuroendocrine tumors of the gastro-entero-pancreatic system. World J Gastroenterol. 2008;14(35):5377–5384.
   PubMed Web of Science ®Google Scholar
• Reznek RH. CT/MRI of neuroendocrine tumours. Cancer Imaging. 2006;6:S163–S177.
   PubMedGoogle Scholar
• Antoch G, Kanja J, Bauer S, et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med. 2004;45(3):357–365.
   PubMed Web of Science ®Google Scholar
• Benjamin RS, Choi H, Macapinlac HA, et al. We should desist using RECIST, at least in GIST. J Clin Oncol. 2007;25(13):1760–1764.
   PubMed Web of Science ®Google Scholar
• Ramage JK, Davies AH, Ardill J, et al; UK and Ireland Neuroendocrine Tumour Society. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut. 2005; 54 Suppl 4:iv1–iv16.
   Web of Science ®Google Scholar
• Oberg K, Jelic S. Neuroendocrine gastroenteropancreatic tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008;19 Suppl 2:ii104–ii105.
   Web of Science ®Google Scholar
• Anthony LB, Strosberg JR, Klimstra DS, et al; North American Neuroendocrine Tumor Society (NANETS). The NANETS consensus guidelines for the diagnosis and management of gastrointestinal neuroendocrine tumors (NETs): well-differentiated NETs of the distal colon and rectum. Pancreas. 2010;39(6):767–774.
   Web of Science ®Google Scholar
• Boudreaux JP, Klimstra DS, Hassan MM, et al; North American Neuroendocrine Tumor Society (NANETS). The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum. Pancreas. 2010;39(6):753–766.
   Web of Science ®Google Scholar
• Kocha W, Maroun J, Kennecke H, et al. Consensus recommendations for the diagnosis and management of well-differentiated gastroenterohepatic neuroendocrine tumours: a revised statement from a Canadian National Expert Group. Curr Oncol. 2010;17(3):49–64.
   PubMed Web of Science ®Google Scholar
• Oberg K, Akerstrom G, Rindi G, Jelic S; ESMO Guidelines Working Group. Neuroendocrine gastroenteropancreatic tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v223–v227.
   Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology.™ Neuroendocrine Tumors. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. 2012. Accessed January 30, 2014.
   Google Scholar